Skip to content

Laser thermotherapy for radioresistant cervical cancer after radiotherapy with or without chemotherapy, or for local recurrence of vagina stump after radiotherapy

Laser thermotherapy for radioresistant cervical cancer after radiotherapy with or without chemotherapy, or for local recurrence of vagina stump after radiotherapy - Laser thermotherapy for radioresistant cervical cancer after radiotherapy with or without chemotherapy, or for local recurrence of vagina stump after radiotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017439
Enrollment
5
Registered
2015-08-01
Start date
2015-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with radioresistant cervical cancer after radiotherapy with or without chemotherapy, or for local recurrence of vagina stump after radiotherapy

Interventions

The newly developed laser thermotherapy equipment 1. Thermotherapy is one time a week. 2. Heating time is from 40 to 50 minutes at 43-45 degrees. 3. Thermotherapy is done 5 or 6 times.

Sponsors

Nagoya University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1)A patient with superficial lesion and a little tumor amount. (2)A patient with no recurrent lesion except for recurrence of uterine cervix in pelvis, or a patients with an expected survival of more than 6 months after this treatment. (3)A patient without distant metastasis. (4))A patient with difficulty of additional radiation therapy. (5)A patient with difficulty of operation or with refusal of operation. (6)A patient without indication of chemotherapy or with refusal of chemotherapy. (7)A patient who has been diagnosed with recurrent or residual cancer of the uterine cervix based on histology (biopsy). (8)A patient who has squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma is limited. (9)A patient with an expected survival of more than 6 months. (10)A female patient aged 20 years or older at the time of enrollment and a patient who has provided written informed consent to partcipate in this study.

Exclusion criteria

Exclusion criteria: (1)A patient who cannot be inserted this equipment through the vagina and can be hard to attain to a lesion. (2)A patient with collagen disease. (3)A patient with active double cancer. (4)A patient whom the investigator considers to be ineligible as a subject.

Design outcomes

Primary

MeasureTime frame
Assessment of safety -Measured by incidence of adverse events before, in and after treatment and until 6 months after the treatment.

Countries

Japan

Contacts

Public ContactYoshiyuki Itoh

Nagoya University Hospital Dept. of Radiology

itoh@med.nagoya-u.ac.jp052-744-2328

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026